CDX2
Showing 1 - 25 of 191
Metastatic Breast Cancer Trial in Rome (HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and
Recruiting
- Metastatic Breast Cancer
- HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
-
Rome, ItalyFondazione Policlinico A. Gemelli - IRCCS
Jun 22, 2023
Eosinophilic Esophagitis Trial (barzolvolimab, Matching Placebo)
Not yet recruiting
- Eosinophilic Esophagitis
- barzolvolimab
- Matching Placebo
- (no location specified)
Mar 7, 2023
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in
Not yet recruiting
- Ovarian Clear Cell Adenocarcinoma
- +14 more
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- +4 more
-
Buffalo, New York
- +1 more
Dec 16, 2022
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)
Not yet recruiting
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Giredestrant
- +6 more
- (no location specified)
Sep 26, 2023
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma Trial
Recruiting
- Metastatic Distal Bile Duct Adenocarcinoma
- +9 more
- Atezolizumab
- +6 more
-
Phoenix, Arizona
- +28 more
Dec 31, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Active, not recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +5 more
- Atezolizumab
- +4 more
-
Tucson, Arizona
- +16 more
Oct 19, 2022
Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in
Completed
- Acute Myeloid Leukemia
- +5 more
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- +4 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Oct 4, 2021
ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United
Active, not recruiting
- ALK-Positive Large B-Cell Lymphoma
- +34 more
- Nivolumab
- Varlilumab
-
Phoenix, Arizona
- +32 more
Jan 3, 2023
Chronic Inducible Urticaria Trial in United States (barzolvolimab, Matching Placebo)
Recruiting
- Chronic Inducible Urticaria
- barzolvolimab
- Matching Placebo
-
Birmingham, Alabama
- +31 more
Jan 20, 2023
Solid Tumor, Adult, Colorectal Cancer, NSCLC Trial in United States (A2B694, xT CDx with HLA-LOH Assay)
Not yet recruiting
- Solid Tumor, Adult
- +19 more
- A2B694
- xT CDx with HLA-LOH Assay
-
Duarte, California
- +9 more
Sep 22, 2023
Chronic Spontaneous Urticaria Trial in Hungary, United States (barzolvolimab, Matching Placebo)
Recruiting
- Chronic Spontaneous Urticaria
- barzolvolimab
- Matching Placebo
-
Birmingham, Alabama
- +44 more
Dec 8, 2022
Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease Trial in Worldwide (PRA023 IV, Companion diagnostic ( CDx),
Recruiting
- Diffuse Cutaneous Systemic Sclerosis
- Interstitial Lung Disease
- PRA023 IV
- +2 more
-
Los Angeles, California
- +13 more
Jul 12, 2022
Phenylketonurias Trial (cohort 1 0.225g, Cohort 2 0.75g, Cohort 3 2.25 g)
Withdrawn
- Phenylketonurias
- cohort 1 0.225g
- +2 more
- (no location specified)
Sep 11, 2020
Crohn Disease Trial in Worldwide (PRA023 IV, Companion diagnostic (CDx))
Active, not recruiting
- Crohn Disease
- PRA023 IV
- Companion diagnostic (CDx)
-
Los Angeles, California
- +36 more
Aug 10, 2022
Acute Myeloid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Buffalo
Completed
- Acute Myeloid Leukemia
- +4 more
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 16, 2020
Barrett Esophagus Trial (Obeticholic Acid, Placebo Administration)
Not yet recruiting
- Barrett Esophagus
- Obeticholic Acid
- Placebo Administration
- (no location specified)
Oct 13, 2022
Ulcerative Colitis Trial in Worldwide (drug, device, other)
Recruiting
- Ulcerative Colitis
- PRA023 IV
- +2 more
-
Mobile, Alabama
- +87 more
May 23, 2022
Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct Trial run by the National Cancer Institute (NCI) (oxaliplatin,
Not yet recruiting
- Biliary Cancer
- +2 more
- oxaliplatin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
May 13, 2023
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Los
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +5 more
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- +3 more
-
Los Angeles, CaliforniaUSC/Norris Comprehensive Cancer Center
Jan 31, 2023
Pancreatic Cancer, Cancer of the Pancreas, Pancreas Cancer Trial in Saint Louis (CDX-301, CDX-1140, Research blood draw)
Recruiting
- Pancreatic Cancer
- +2 more
- CDX-301
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 17, 2023
Chronic Spontaneous Urticaria Trial in Germany, United States (CDX-0159, Normal Saline)
Completed
- Chronic Spontaneous Urticaria
- CDX-0159
- Normal Saline
-
Birmingham, Alabama
- +13 more
Jan 24, 2023
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Tucson (Tadalafil 20 MG)
Not yet recruiting
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Tadalafil 20 MG
-
Tucson, ArizonaArizona Cancer Center at UMC North/University Medical Center
Feb 1, 2023
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 Trial in United States (Glembatumumab Vedotin, Laboratory Biomarker
Completed
- Recurrent Uveal Melanoma
- Stage IV Uveal Melanoma AJCC v7
- Glembatumumab Vedotin
- +2 more
-
Phoenix, Arizona
- +24 more
Jul 30, 2020
Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)
Recruiting
- Melanoma
- Metastatic Melanoma
- CDX-301
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 12, 2023